


Cancel pages 11-43 and replace them with attached pages 11-42.

Please renumber pages 44 and 45 as pages 43 and 44, respectively.

IN THE CLAIMS:

Please amend claims 1-8, 10 and 15 as follows:

- 
1. (Amended) Method of using an oligoribo- or oligodeoxyribonucleotide which hybridizes with the mRNA which codes for the protein Ki-67, or a physiologically acceptable salt thereof, for the preparation of a medicament for destroying proliferating cells.
 2. (Amended) Method according to claim 1, wherein the nucleotide sequence of the oligoribo- or oligodeoxyribonucleotide is complimentary to SEQ ID NO 1.
 3. (Amended) Method according to claim 2, wherein the nucleotide sequence of the oligoribo- or oligodeoxyribonucleotide is complimentary to the section from position 197 to 9962 of SEQ ID NO 1.
 4. (Amended) Method according to anyone of claims 1 to 3, wherein the nucleotide sequence of the oligoribo- or oligodeoxyribonucleotide contains 12 to 66 nucleotides.
 5. (Amended) Method according to anyone of claims 1-3, wherein the nucleotide sequence of the oligoribo- or oligodeoxyribonucleotide contains 17 to 46 nucleotides.

6. (Amended) Method according to any one of claims 1-3, wherein the oligoribo- or oligodeoxyribonucleotide has the sequence (SEQ ID NO:3) (5'-ACC AGG CGT CTC GTG GGC CAC AT).

7. (Amended) Method according to anyone of claims 1-3, wherein one or more phosphate groups of the oligoribo- or oligodeoxyribonucleotide are replaced by at least one selected from the group consisting of phosphothioate, methylphosphonate, phosphoramidate, methylene(methylimino) and guanidine group(s).

8. (Amended) Method according to anyone of claims 1-3, wherein the oligoribo- or oligodeoxyribonucleotide has a terminal 3'-3' and/or 5'-5' internucleotide linkage.

10. (Amended) Method according to anyone of claims 1-3, for treatment of tumours, autoimmune diseases, cicatrization, inflammations, allergies, rheumatic diseases and rejection reactions following transplantations.

15. (Amended) Oligoribo- or oligodeoxyribonucleotide according to claim 14, [characterized in that] wherein it contains the sequence (SEQ ID NO:3) (5'-ACC AGG CGT CTC GTG GGC CAC AT).

EXPLANATION OF AMENDMENT:

Page 7, lines 1-3 of the specification has been amended as shown by [deletions] and insertions.

start-2- anti (SEQ ID NO:3) 5'-ACC AGG CGT CTC GTG GGC CAC AT

start-2-sense (SEQ ID NO:4) 5'-ATG TGG CC ACG AGA CGC CTG GT

missense (SEQ ID NO:5) 5'-AGT ACT CAG TAA CGC CTA CGG TAA G

The claims have been amended as shown by [deletions] and insertions.

1. (Amended) [Use] Method of using an oligoribo- or oligodeoxyribonucleotide which [is capable of hybridizing] hybridizes with the mRNA which codes for the protein Ki-67, or a physiologically acceptable salt thereof, for the preparation of a medicament for destroying proliferating cells.
2. (Amended) [Use] Method according to claim 1, [characterized in that] wherein the nucleotide sequence of the oligoribo- or oligodeoxyribonucleotide is complimentary to SEQ ID NO 1.
3. (Amended) [Use] Method according to claim 2, [characterized in that] wherein the nucleotide sequence of the oligoribo- or oligodeoxyribonucleotide is complimentary to the section from position 197 to 9962 of SEQ ID NO 1.
4. (Amended) [Use] Method according to anyone of claims 1 to 3, [characterized in that] wherein the nucleotide sequence of the oligoribo- or oligodeoxyribonucleotide contains 12 to 66 nucleotides.

5. (Amended) [Use] Method according to anyone of claims 1-3[4], [characterized in that] wherein the nucleotide sequence of the oligoribo- or oligodeoxyribonucleotide contains 17 to 46 nucleotides.
6. (Amended) [Use] Method according to any one of claims 1-3[5], [characterized in that] wherein the oligoribo- or oligodeoxyribonucleotide has the sequence (SEQ ID NO:3) (5'-ACC AGG CGT CTC GTG GGC CAC AT).
7. (Amended) [Use] Method according to anyone of claims 1-3[6], [characterized in that] wherein one or more phosphate groups of the oligoribo- or oligodeoxyribonucleotide are replaced by at least one selected from the group consisting of phosphothioate, methylphosphonate, phosphoramidate, methylene(methylimino) and[/or] guanidine group(s).
8. (Amended) [Use] Method according to anyone of claims 1-3[7], [characterized in that] wherein the oligoribo- or oligodeoxyribonucleotide has a terminal 3'-3' and/or 5'-5' internucleotide linkage.
10. (Amended) [Use] Method according to anyone of claims 1-3[8], [characterized in that] for treatment of tumours, autoimmune diseases, cicatrization, inflammations, allergies, rheumatic diseases and rejection reactions following transplantations.
15. (Amended) Oligoribo- or oligodeoxyribonucleotide according to claim 14, [characterized in that] wherein it contains the sequence (SEQ ID NO:3) (5'-ACC